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One aim of tumour immunology continues to be the definition of
antigens that are expressed in tumour cells and elicit immune
responses in the autologous host (Kawakami and Rosenberg,
1997; Old and Chen, 1998). Using specific cytotoxic T-lympho-
cytes (CTL) and cultured tumour cells from individual patients,
several such antigens have been identified, particularly in malig-
nant melanoma (Kawakami and Rosenberg, 1997). These antigens
are attractive candidates for molecularly defined vaccine-based
immunotherapy of cancer. However, the direct definition of
antigens recognized by CTLs is technically demanding and not
feasible for many common types of malignancies.
SEREX (serological identification of tumour antigens by
expression cloning) was introduced by Sahin et al (1995) as an
alternative approach to identify antigens recognized by autologous
serum antibodies. Basically, a cDNA expression library is
constructed from tumour material and screened with the patient’s
serum, thus enabling cloning of genes encoding proteins which
elicit B-cell responses. The validity of the approach for identifica-
tion of tumour antigens giving rise to cell-mediated immune
responses as well was exemplified by finding previously known
CTL antigens among the first antigens isolated by SEREX (Sahin
et al, 1995). Additionally, SEREX-defined antigens have later
been shown to elicit T-cell responses (Jager et al, 1998).
SEREX has been used to screen expression libraries from
various malignancies, including renal cell carcinoma (Sahin et al,
1995; Scanlan et al, 1999), Hodgkin’s disease (Sahin et al, 1995),
malignant melanoma (Chen et al, 1998; Sahin et al, 1995), adult T-
cell leukaemia/lymphoma (Itoh et al, 1999), oesophageal squamous
cell carcinoma (Chen et al, 1997), lung (Gure et al, 1998) and
colon cancer (Scanlan et al, 1998). Variations of the original
method include screening of subtracted testis cDNA libraries or
libraries made from tumour cell lines (Chen et al, 1998; Itoh et al,
1999; Tureci et al, 1998). Over 1000 antigens belonging to several
categories have been identified, including differentiation antigens,
mutational antigens, overexpressed antigens and the so-called
cancer/testis family of tumour antigens (Old and Chen, 1998). The
latter category consists of genes or gene families that are uniquely
expressed in normal testicular tissue and in malignant tumours.
The high number of tumour antigens identified provide ample
evidence for the recognition of cancer by the host immune system.
However, the high number of antigens also necessitates thorough
characterization of the identified genes to establish a potential role
in cancer biology and immunotherapy.
The present paper describes the application of SEREX to screen
for immunogenic tumour antigens in prostate cancer. The original
method was modified to include a cell line derived cDNA library
and sera from allogeneic patients with early and late stages of the
disease to potentially increase the yield of antigens common to a
larger proportion of prostate tumours. Among four genes identi-
fied, the gene encoding nucleolar protein No55 was further charac-
terized in terms of expression pattern, serological response in
prostate cancer patients and chromosomal localization.
MATERIALS AND METHODS
Patient sera, biopsy material and cell lines
The study was approved by the ethics committee for health region
II, Oslo, Norway. Sera from patients with histologically verified
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Central Laboratory, The Norwegian Radium Hospital (NRH).
Biopsies from normal prostate tissue (n = 5), primary prostate
tumours (n = 6) and metastatic lesions (n = 2) were provided by
the Department of Medical Oncology, NRH. Tissue areas adjacent
to the material used for mRNA extraction were analysed for
malignant cells by light microscopy of haematoxylin/eosin-stained
paraffin sections. Matched cDNA preparations from primary
tumour and normal prostate tissue of three individual patients were
purchased from Clontech Laboratories, Palo Alto, CA, USA.
The following cell lines from human malignancies were used:
prostate cancer: DU145 (ATCC HTB-B1), LNCaP (ATCC CRL-
1740), PC-3 (ATCC CRL-1435) and PC-3m (provided by Dr IJ
Fidler, MD Anderson Cancer Center, Houston, Texas, USA);
Cervix cancer: HeLa (ATCC CCL-2); Pancreatic cancer: Capan-1
(ATCC HTB-79). Cell lines from lymphoid malignancies (Reh,
BV173, Tom1) have been described recently (Rosok et al, 1999).
cDNA library construction and immunoscreening
Total RNA was extracted from DU145 cells using the acid
guanidinthiocyanat method (Chomczynski and Sacchi, 1987) and
mRNA isolated with oligo-dT-Dynabeads (Dynal, Oslo, Norway).
The cDNA library was constructed in the λ ZAP expression vector
(Statagene, LaJolla, CA, USA). The cDNA library had 1.5× 106
primary recombinant clones and was amplified once before
screening.
Sera from one patient with metastatic disease (MD1) and three
patients with localized disease (LD1–3) were used for immuno-
screening as described by Gure et al (1998). Briefly, sera diluted
1:10 were extensively absorbed against bacteria transfected with
wild type λ ZAP phage, further diluted to a final titre of 1:500 or
1:100 and a minimum of 4 × 105 recombinant plaques screened
with each dilution. After washing, the filters were incubated with
alkaline phosphatase conjugated goat anti-human IgG and
immunoreactive plaques visualized by incubation with 5-bromo-4-
chloro-3-indolyl-phosphate and nitroblue tetrazolium.
Positive phages were subcloned until homogeneity, converted to
plasmid clones in pBluescript using the Ex-Assist helper phage
(Stratagene) and sequenced by means of BigDye™ Terminator
Cycle Sequencing (Perkin Elmer Applied Biosystems,
Warrington, UK) on an ABI PrismTM 310 Genetic Analyser
(Perkin Elmer). DNA and protein sequences were analysed using
DNASIS for Windows 2.1 (Hitachi Software Engineering
America, San Bruno, CA, USA) and compared to sequences in the
GenBank and other public databases using the BLAST program.
Cloning of No55 open reading frame (ORF) and rapid
amplification of cDNA ends (RACE) by polymerase
chain reaction (PCR)
The ORF of the No55 gene was amplified from normal testis
Ready-Marathon-cDNA (Clontech) and a metastatic lesion of
patient MD1 by PCR. Primers No55ORFf (5′ -TCCGGAGAGC-
CGGCGGCGCGGCGG-3′ ) and No55ORfr (5′ -CACCAGGCT-
TCCCAAGCTTGAGCGGTGTG-3′) were designed to cover the
complete ORF. PCR products were cloned into the pGEM-T® Easy
vector (Promega, Madison, WI, USA) and the ligation mixture
used to transform competent Escherichia coli DH10B cells (Life
technologies, Rockville, MD, USA). Four clones containing the
desired PCR fragment were sequenced from each experiment.
RACE PCR was performed using cDNA from DU145 ligated
into λ ZAP, but not in vitro packaged into phage particles, with
primers T7 (5′ -GTAATACGACTCACTATAGGGC-3′ ) and
No55ORFr. PCR products were analysed by gel electrophoresis
and the longest DNA fragments cloned in E. coli DH10B cells as
above. Twelve clones with the longest PCR fragments were
sequenced from their 5′ ends.
Expression analysis of No55 in tissues and cell lines
Northern analysis of No55 in normal tissues was performed using
commercially available blots (Clontech). For expression studies in
cell lines, 10 µ g total RNA separated by formaldehyde/agarose
gel electrophoresis and transferred to nitrocellulose membranes.
Hybridization was performed with a 32P-labelled 1530 bp fragment
covering the complete ORF of the No55 gene. Standardization was
achieved using a 32P-labelled fragment of β -actin cDNA (Rosok 
et al, 1999). Quantification was performed on a Storm 840
Phosphorimager using ImageQuant 5.0 (Molecular Dynamics
GmbH, Krefeld, Germany).
Expression of No55 in tumour biopsies was analysed by reverse
transcriptase/polymerase chain reaction (RT/PCR). mRNA was
extracted using the mRNA-Quick-Prep Kit (Amersham-
Pharmacia-Biotech, Oslo, Norway) and treated with RNase-free
Dnase I (Boehringer-Mannheim, Mannheim, Germany). cDNA
synthesis was performed with First-Strand cDNA Synthesis Kit
(Amersham-Pharmacia-Biotech). For one set of experiments,
primers No55961f (5′ -CCAGCTACATGCTCTTCGACCCCA-3′ )
and No55ORFr were used to amplify a 408 basepair (bp) fragment
from the 3′ end of the No55 ORF. A second set of experiments
used the primers No55ORFf and No55ORFr covering the
complete ORF. The number of cycles (34 and 30, respectively)
was determined in preliminary experiments to be in the loga-
rithmic phase of the PCR. After agarose gel electrophoresis PCR
products were blotted to nitrocellulose for hybridization with a
32P-labelled fragment covering the 3′ end of the No55 ORF.
Quantification was performed on a Storm 840 Phosphorimager as
above. The amount of cDNA used per reaction was standardized
according to the expression level of β -actin with primers β -actinf
(5′ -GAGCAAGAGAGGCATCCTCAC-3′ ) and β− actinr (5′ -
TGCCTCAGGGCAGCGGAACCG-3′ ) or human ribosomal
protein S9 using commercially available primers (Clontech).
Serological analysis for anti-No55 antibodies
Analysis of anti-No55 IgG antibodies in sera from patients with
prostate cancer and healthy male controls was performed using a
plaque assay (Gure et al, 1998). Recombinant phages encoding
No55 and irrelevant phages were plated on LB-agar plates in a 1:5
ratio. Filters were hybridized to preabsorbed serum diluted 1:100
and positive plaques visualized as above. For recording as a posi-
tive result, positive and negative plaques in approximately a 1:5
ratio were required. In some positive cases incomplete circles were
seen representing positive plaques in direct contact with negative
plaques. Sera giving uniform faint staining of all plaques or
completely negative filters were recorded as negative.
Chromosomal localization of the gene encoding No55
Radiation hybrid mapping was performed with primers No55f (5′ -
TAATCGTAGCTGAGGCAG G-3′ ) and No55r-1 (5′ -CAGAGA-
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(Research Genetics, Huntsville, AL, USA). Map localization was
calculated on the Stanford Human Genome Center RHServer
(http://www-shgc.stanford.edu). Additionally, the human
RPCI1,3–5 PAC libraries were screened by PCR using the same
primer pair. Pools for this screening were obtained from the
German Resource Center (Berlin, Germany). Cytogenetic assign-
ment of PAC clone 228H19 derived from the PAC library screen
was performed by FISH using biotinylated PAC DNA as probe and
subsequent R-banding as described recently (Harder et al, 1997).
RESULTS
Immunoscreening of the DU145 cDNA library
The DU145 cDNA expression library was screened with sera from
four prostate cancer patients, and the results of immunoscreening
are shown schematically in Table 1. cDNA inserts were grouped
based on restriction mapping, partial sequencing and DNA–DNA
hybridization. All sequences identified were cDNAs of known
human genes. Serum from patient MD1 reacted with 12 plaques,
representing two independent cDNA clones. Eleven of these
clones contained the full-length cDNA of TDP-43, a human DNA
binding protein known to be widely expressed in normal tissues
(Ou et al, 1995). The last clone was derived from the mRNA of the
No55 gene (Ochs et al, 1996). Sera from the three patients with
localized disease (LD1, LD2 and LD3) reacted with 1, 17 and 0
plaques, respectively. For patient LD1, the only positive clone
contained the full-length cDNA insert of Drebrin, an actin-binding
protein known to be differentially expressed in neuronal develop-
ment (Toda et al, 1993). The 17 plaques from screening with
serum from patient LD2 originated from two different genes, No55
and the recently identified regulatory subunit of serine/threonine
protein phosphatase 4 (PP4R) (Kloeker and Wadzinski, 1999).
Northern blot analysis showed PP4R to be broadly expressed in
human tissues with predominant expression in testis, peripheral
blood leukocytes and spleen (Figure 1). The TDP-43, Drebrin and
PP4R cDNA clones were not analysed further.
Sequencing
Further work focused on the 18 phage clones harbouring No55
cDNAs. The two clones with the longest cDNA inserts (LD2–3
and LD2–14) were sequenced and compared to the No55 sequence
from the human bladder carcinoma cell line T24 (Table 1). Both
cDNA clones terminated at position 2005 of the T24 sequence,
probably as a result of hybridization of the oligo-dT adaptor
primer used for first-strand synthesis to an internal 18 nucleotide
adenine repeat. Compared to the T24 sequence, clone LD2–14
contained 43 additional nucleotides in the 5′ untranslated region
(5′ UTR). In both DU145 derived clones a base substitution
(A→ G) was detected at position 557 (one being A of ATG initia-
tion codon), resulting in an amino acid substitution (Gln→ Arg)
at position 186 of the predicted primary structure of the No55
protein. A second substitution (G→ C) was detected in both
DU145 clones at position 1345, just 3′ of the TGA stop codon.
A 5′ RACE-PCR approach was used to establish the extent of the
5′ UTR not covered by the clones from the immunoscreening of the
DU145 library. Twelve overlapping cDNA clones were sequenced
at their 5′ ends and the longest insert covered an additional 73
nucleotides compared to the T24 sequence. The 5′ UTR did not
contain an ATG initiation codon or stop codons in any of the three
possible reading frames. The complete sequence of the No55
mRNA from DU145 has been deposited to EMBL Genbank
(accession number AJ250583).
To explore the possibility of sequence mutations as the reason
for a serological response to No55, the complete ORF was
sequenced both in normal testis tissue pooled from four caucasian
males and in a metastatic lesion of the seroreactive patient MD1.
In both cases, four PCR products were sequenced with an average
of one random PCR artifact per clone. In testis, clones corre-
sponding both to the sequence at nucleotide position 557 of T24
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Figure 1 Northern blot analysis in normal human tissues of nucleolar
protein No55 (top panel, transcript length 2.6 kb) and the regulatory subunit
of serine/threonine protein phosphatase 4 (PP4R, lower panel, transcript
length 3.6 kb). PBL = peripheral blood leukocytes
Table 1 Results of immunoscreening of the DU145 expression cDNA library with sera from four prostate cancer patients
Patient Screening Clones Positive Gene identified/ Comments
titre screened (n) clones (n) Accession no.
MD1 1:500 1 × 106 11 TDP-43/U23731 TAR DNA binding protein, widely expressed in normal tissues
1 No55/U47621 Nucleolar protein 55, see text
LD1 1:500 5 × 105 0
1:100 4 × 105 1 Drebrin/NM_004395 Actin binding protein, differentially expressed in neuronal
development
LD2 1:500 5 × 105 8 No55/U47621 Nucleolar protein 55, see text
1:100 4 × 105 8 No55/U47621
1 PP4R/AF111106 Regulatory subunit of serine/threonine phosphatase 4, widely
expressed in normal tissues
LD3 1:500 5 × 105 0
1:100 4 × 105 0(TAT CAG GGG) and DU145 (TAT CGG GGG) were found,
indicative of an allelic polymorphism this position. In patient MD1
all four clones were identical to the T24 sequence (TAT CAG
GGG). Other deviations from the published No55 ORF were not
found, neither in testis nor in tumour material.
Expression pattern of No55 in normal tissues and cell
lines
Northern analysis of No55 in normal human tissues is depicted
in Figure 1. A 2.6 kb transcript was detected with the strongest
signals in ovaries, pancreas and prostate and weaker signals in
testis, heart, kidney colon, spleen and placenta. Quantified expres-
sion levels were similar in ovaries and pancreas, 2-fold higher for
ovaries relative to prostate and 8-fold higher in ovaries relative to
placenta. No expression above background was recorded for the
other human tissues tested. Expression of No55 was also found in
three additional prostate cancer cell lines (PC-3, PC-3m and
LNCaP) (Figure 2).
Expression of No55 in biopsies from normal prostate
tissue and prostate cancer
Due to the low amount of tissue available, expression of No55 in
biopsies from normal prostate tissue, primary prostate tumours
and metastatic lesions was analysed by semi-quantitative RT-PCR
(Figure 3A). Expression was found in five out five biopsies from
normal prostate tissue and six out of six primary tumour biopsies
at varying levels. Two primary tumours expressed No55 at levels
3–4 times higher than the average level for normal prostate tissue.
Expression in the four remaining samples was similar to normal
tissue using a 3-fold increase relative to the normal prostate tissue
samples as a cut-off value. For two metastatic lesions (from the
seroreactive patient MD1 and the seronegative patient MD25),
No55 expression was found to be 4- and 5-fold higher, respec-
tively, compared to normal prostate tissue.
In a second set of experiments the complete No55 ORF was
amplified, and the expression level compared in matched biopsies
from normal prostate tissue and primary tumours from individual
patients and metastatic tissue from other patients (Figure 3B). For
the three paired samples, no significant increase in expression was
detected in primary tumours compared to normal tissue. Again,
expression in the two metastatic lesions (from patients MD1 and
MD25) was found to be increased 5- and 6-fold, respectively,
compared to the average of the three normal prostate tissue
samples.
Screening for anti-No55 antibodies in sera from
patients with prostate cancer and healthy controls
A plaque assay was used to test for IgG antibodies against No55
protein in sera of patients with prostate cancer and healthy male
volunteers. Preabsorbed sera were assayed in a dilution of 1:100.
Among the 45 patients with local disease, six had detectable anti-
No55 antibodies, as had one out of two patients with metastatic
disease. Altogether, a positive result was obtained for seven out
of 47 patients (15%). None of the 20 healthy male controls had
detectable anti-No55 antibodies.
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Figure 2 Northern blot analysis of nucleolar protein No55 (right panel) in
cell lines from prostate cancer (Du145, PC-3, PC-3m, LNCaP). Expression in
HeLa (cervix cancer), BV173 and Tom1 (lymphoid malignancies) and Capan-
1 (pancreatic cancer) are shown for comparison. β -actin expression as
control of RNA quality and loading (left panel)
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Figure 3 Expression of nucleolar protein No55 in biopsies from normal
prostate (NP), primary prostate tumours (PT) and prostate cancer
metastases (MD) by RT-PCR. H2O included as negative control. (A)
Fragments from the 3′ end of the No55 open reading frame were amplified by
RT-PCR, blotted and hybridized to a 32P-labelled fragment from No55 cDNA
(top panel). β -actin expression visualized on an ethidium bromide stained
agarose gel (lower panel). (B) Fragments covering the No55 open reading
frame were amplified by RT-PCR, blotted and hybridized to a 32P-labelled
fragment from No55 cDNA (top panel). S9 expression visualized on an
ethidium bromide stained agarose gel (lower panel)Chromosomal localization of the gene encoding No55
Southern analysis of DNA from peripheral blood leukocytes and
cell lines DU145, Hela and Reh indicated that the No55 gene is a
single copy gene and gave no evidence for amplification of the
gene in cell lines with a high No55 expression (data not shown).
Radiation hybrid mapping with an STS derived from the No55
cDNA sequence placed the No55 gene on the long arm of chromo-
some 17 in close proximity (distance 7cR, LOD-Score 10.47) to
the STS SHGC-30259. This latter STS located in the interval
between D17S800 and D17S930 (62.9–64.3 cM) at 2171
cR10 000 (F) on the GeneMap99 RH map is specific for the
human JUP (Junction plakoglobin) gene. The JUP gene has been
cytogenetically assigned to the chromosomal region 17q21
(http://www.ncbi.nlm.nih.gov/cgi-bin/UniGene). In line with this
location, PAC 228H19 specific for the No55 STS was mapped to
17q21 by FISH and subsequent R-banding. Further support for the
location of No55 on chromosome 17 comes from sequence
comparisons using the BLASTN algorithm, that revealed the
human chromosome 17 specific BAC-clone RP11-156E6
(AC012192) to contain the No55 gene.
DISCUSSION
In the present study sera from prostate cancer patients were used to
identify tumour-associated antigens expressed in a prostate cancer
cell line. The choice of cell line DU145 and sera was based on the
following rationale. DU145 is derived from a prostate cancer
metastasis, and thus potentially expresses a spectrum of antigens
representative of advanced disease. Sera used for screening
included patients with limited disease, to isolate antigens with
relevance to early stages of the disease. Thereby, it was expected
to increase the yield of antigens that are present in early stages of
the disease and that are retained throughout tumour progression.
The yield of immunoreactive proteins in the present study appears
to be lower than reported in studies of SEREX in other malignan-
cies. Using cDNA libraries from autologous tumour, testis tissue or
cell lines, a larger number of different immunogenic proteins are
found per patient serum. To our knowledge, the four different genes
isolated in this study did not correspond to any of the genes isolated
by other investigators, and did not match any sequences released in
the publicly available part of the SEREX database (http://www-
ludwig.unil.ch/SEREX). These differences may result from the
experimental design, i.e. the use of allogeneic sera from early-stage
patients and a cell line cDNA library. This could indicate that the
number of immunogenic proteins retained in the tumour throughout
progression may be low. There may also be differences in the
immunobiology of prostate cancer and other types of cancer.
Of the four genes identified by immunoscreening, the gene
encoding the nucleolar protein No55 was further analysed. No55
was initially described as a 55 kD nucleolar protein in human cell
lines recognized by IgG antibodies in the serum of a female patient
with interstitial cystitis (IC) (Ochs et al, 1996). The cDNA
encoding the No55 protein was cloned by immunoscreening of an
expression library from the bladder carcinoma cell line T24 and
contained an ORF corresponding to a predicted molecular mass of
50 kD (Ochs et al, 1996). The primary structure of the No55
protein reveals 87% sequence identity and 92% sequence simi-
larity to SC65, a protein isolated from the synaptonemal
complexes (SC) of meiotic chromosomes of rat testicles (Chen et
al, 1992).
No55 is expressed in several normal human tissues. The highest
mRNA expression levels were detected in ovaries, pancreas and
prostate and lower levels in other tissues. Several tissues tested did
not reveal detectable No55 transcripts by Northern blot analysis.
This expression pattern in human tissues is markedly different
from the expression pattern of the homologous protein SC65 in
rats. Rat SC65 mRNA was detected at the highest levels in testis,
brain and heart, and a lower level in liver (Chen et al, 1992).
However, it cannot be excluded that more human tissues express
No55 mRNA at low levels not detectable by Northern blot
analysis.
No55 expression could be demonstrated in all analysed prostate
cancer cell lines and tumour samples from prostate cancer,
including primary tumours and metastatic tissue. No55 expression
thus does not appear to be lost during malignant transformation of
prostate epithelial cells and subsequent tumour growth. Based on
the standardization by mRNAs for β -actin or ribosomal S9 protein
used for the semi-quantitative approach, there was clear over-
expression of No55 in metastatic lesions. Although a subset of
primary tumour biopsies contained No55 transcripts at levels
considerably higher than the average of normal prostate tissue
samples, no clear difference in expression level was found for
three sets of matched biopsies from primary tumours and normal
prostate tissue from the same individuals. A firm conclusion on the
expression level of No55 in primary tumours is hampered for
several reasons. First, the standardization of RT-PCR experiments
using housekeeping genes such as β -actin or S9 is not reliable in
all cases, as variations in expression levels of these genes do occur
(Spanakis and Brouty-Boye, 1994). Secondly, the relative amounts
of stroma cells may vary between biopsy specimens. In the present
study, morphological analysis of all samples used for RNA extrac-
tion showed differences in the amount of non-epithelial cells,
comparing both different samples and different areas of each indi-
vidual sample. The availability of a specific antibody for use in
immunohistochemistry will potentially allow a better assessment
of the relative expression levels of No55 in metastatic lesions,
primary tumours and normal prostate tissue.
The function of No55 in tumour cells is unknown. However,
No55 displays similarities to SCP-1, a member of the SEREX-
defined cancer/testis family of tumour antigens (Tureci et al,
1998). The SCP-1 protein is localized in the SC of meiotic chro-
mosomes in human testicles and in the nucleus of malignant cells.
It has been proposed that ectopic expression of SCP-1 may inter-
fere with chromosome segregation during mitosis (Tureci et al,
1998). Similarly, SC65, the rat homologue of No55, has been
shown to be localized in the SC and No55 is expressed in ovaries
and testicles, both organs involved in gametogenesis. In analogy,
one may speculate that No55 could contribute to mitotic insta-
bility. No55 expression may also be related to the proliferative
activity of somatic cells. Other nucleolar antigens, such as p120
and p145, have been found to be associated with proliferating cells
of normal tissues and to be expressed in a variety of malignant
tumours (Freeman et al, 1989). Both proteins have been shown to
be of relevance to prostate cancer and p120 appears to be an addi-
tional prognostic marker for carcinoma of the prostate (Qiao et al,
1994; Kallakury et al, 1999). Further work is required in order to
establish the function of No55 in cancer cells in general and carci-
noma of the prostate in particular.
There is considerable overlap in the repertoire of autoantibodies
found in patients with autoimmune disease and cancer patients
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serum from a patient with IC, a condition where autoimmune
destruction of the bladder wall is believed to be play a role in the
pathogenesis (Theoharides et al, 1998). However, little is known
about the incidence of anti-No55 antibodies in patients with IC or
autoimmune disease in general. Autoantibodies with a nucleolar
staining were found in 7% of patients with IC, but the specificities
of the individual patients’ antibodies have not been reported (Ochs
et al, 1994). To the best of our knowledge, anti-No55 antibodies
have not been described in patients with other autoimmune disease
or in normal controls. In contrast, autoantibodies of the IgG
subclass against No55 were found in 15% of prostate cancer
patients in the present study and none of the seven patients with
anti-No55 antibodies identified had a history of IC or other
autoimmune disease. However, the finding of anti-No55 anti-
bodies in patients with IC raises concern as to potential use of
No55 as a target antigen in immunotherapy of prostate cancer.
No direct evidence presented in this paper indicates that No55 is
mutated in prostate cancer. The only sequence differences identified
in the ORF probably result from an allelic polymorphism. However,
the No55 gene is located at position 17q21, a locus reported to be
partially deleted in 50% of prostate cancers (Gao et al, 1995). A
tumour suppressor gene (TSG) with relevance to the development of
prostate cancer has been suspected in this region and BRCA-1 is a
candidate TSG at this locus (Murakami et al, 1995; Fan et al, 1998;
Uchida et al, 1999). Whether deletions in region 17q21 in prostate
cancers affect noncoding regions of the No55 gene, i.e. regulatory
regions of gene expression, remains to be elucidated.
Three genes isolated in the present study, TDP-43, Drebrin and
PP4R, have not yet been analysed in detail although the corre-
sponding proteins prove to be immunogenic in individual prostate
cancer patients. Drebrin is differentially expressed during neuronal
development and, through binding to actin filaments, the protein is
involved in neuronal morphogenesis (Shirao, 1995). The cloning
of Drebrin by SEREX may relate to the neuroendocrine differenti-
ation reported for DU145 and the fact that approximately 50% of
prostate cancer patients show neuroendocrine elements in their
tumours (Cussenot et al, 1998; Hoosein, 1998). PP4R has recently
been cloned but its function in human tissues is not clear (Kloeker
and Wadzinski, 1999). PP4R is broadly expressed in human tissues
including the prostate gland and the PP4R primary sequence
contains 13 non-identical repeats of approximately 40 amino acids
in length. Repetitive elements in the primary structure have been
found as a predominant feature in other tumour antigens recog-
nized by SEREX (Gure et al, 1998).
In conclusion, among four immunogenic proteins identified by
serological analysis, No55 displays a restricted expression profile
in normal and malignant tissues, is expressed in early and late
stages of prostate cancer and is immunogenic in a subset of
patients. These data, together with the chromosomal localization of
the No55 gene, warrant further investigation of the potential role of
No55 in the biology and tumour immunology of prostate cancer.
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